Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients

Geriatrics and Gerontology International

Volumn 11, Issue 1, 2011, Pages 55-62

  Ito, Hiroyuki ^a   Ohno, Yasuhiro ^a   Yamauchi, Takaaki ^a   Kawabata, Yumiko ^a   Ikegami, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biguanide; Insulin resistance; Lactic acidosis; Metformin; Type 2 diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; LACTIC ACID; METFORMIN; SULFONYLUREA;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; GROUPS BY AGE; HUMAN; HYPOGLYCEMIA; JAPANESE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; METFORMIN; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650243075     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00635.x     Document Type: Article

References (20)

1. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
2. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
5. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N. Obesity and type 2 diabetes in Japanese patients. Lancet 2003; 361: 85.
6. Kaku K, Tajima N, Kawamori R. Melbin observational research (MORE) study of metformin therapy in patients with type 2 diabetes mellitus. J Japan Diab Soc 2006; 49: 325-331 (in Japanese).
7. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
8. Johanen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33-37.
9. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 3: CD002966.
10. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162: 434-437.
11. Misbin RI. Phenformin-associated lactic acidosis: pathogenesis and treatment. Ann Intern Med 1977; 87: 591-595.
12. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Systematic review and meta-analysis. Arch Intern Med 2003; 163: 2594-2602.
13. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
14. Perriello G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
15. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
16. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-2081.
17. Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005; 82: 923-934.
18. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
19. Krentz AJ. Insulin Resistance. Oxford: Blackwell Science Ltd, 2002; 169-170.
20. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-294.